This study is checking how well a new medicine, **JNJ-79635322**, works compared to another medicine called **teclistamab** for people with relapsed or refractory multiple myeloma (RRMM). Multiple myeloma is a type of cancer that affects certain blood cells in the bone marrow. The study is for people who have already tried 1 to 3 other treatments, including a special kind of medicine called an anti-CD38 antibody.

• The study requires visits to the hospital for tests and treatments.
• Participants should not have had major surgery recently.
• People with certain other health problems cannot join.

To join, participants must have a confirmed diagnosis of multiple myeloma and meet specific health criteria. The study will compare the effects of both medicines, looking at how well they work and their side effects. Before joining, it's important to talk to a doctor and understand the study’s risks and requirements.